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INTRODUCTION:  Primary  breast  angiosarcoma  is  a rare  form  of breast cancer,  accounting  for  only  0.04%
of all  malignant  breast  tumours.
PRESENTATION  OF  CASE:  A 28-year-old  woman  presented  with  a  progressive  lump  in the  right breast
for  one  month.  Fine  needle  aspiration  cytology  (FNAC)  was  highly  suspicious  of angiosarcoma,  and  this
diagnosis  was conﬁrmed  on  core  needle  biopsy.  Modiﬁed  radical  mastectomy  was performed  as  sole
treatment.
DISCUSSION:  Primary  breast  angiosarcoma  is  a  rare  type  of breast  malignancy,  usually  occurring  in  the
third to fourth  decade  and  only  reported  in  women.  The  histological  features  of  angiosarcoma  of  the
breast  are  conventionally  graded  I, II or III. Total  mastectomy  appears  to be  the  only  treatment  conferring
beneﬁt,  chemotherapy  and  radiation  therapy  being  of little  proven  value  to  date.  The  5-year  disease-free
survival  for  grade  I tumours  can  be as  high  as  76%,  and  up to  70%  for  grade  II  tumours  whereas  for  grade
III  tumours  it  is reportedly  about  15%.
CONCLUSION:  Primary  angiosarcoma  of the breast  is a rare  malignancy  with  a poor  prognosis,  even
after  complete  resection.  Surgery  is  the mainstay  of treatment  with  a  limited  role  for  chemotherapy
and  radiotherapy.
sevie© 2013 Published by El
. Introduction
Malignant breast lesions that arise from stromal tissues are
xtremely rare, accounting for <1% of all malignant breast tumours.
ost mammographically and clinically evident intraparenchymal
ascular tumours prove to be malignant angiosarcomas. Angiosar-
oma is the most common sarcoma to occur in the breast, but is
elatively rare. Angiosarcoma usually presents as a palpable mass,
ut 17% of cases may  present with a bluish discolouration or bruis-
ng of the overlying skin. This malignant tumour occurs primarily
n young women. Ultrastructural examination and immunostaining
or factor VIII-related antigen helps with the diagnosis of angiosar-
oma of the breast, a neoplasm which carries poor prognosis.
. Case report
.1. Presentation of caseA 28-year-old female presented with a lump in the right breast
or a month, rapidly progressive. There was no history of breast
urgery or breast irradiation. On examination the 5 cm × 5 cm mass
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in the upper inner quadrant of the right breast was  ﬁrm, non ten-
der and not attached to the skin or deep structures, and there
was no evidence of nipple retraction, skin thickening or axillary
lymphadenopathy. Routine blood investigations and a chest X Ray
were within normal limits, as were a serum CEA and serum CA
15-3. Mammography of the right breast showed an ill deﬁned, non
spiculated and non-calciﬁed lobulated mass, 5 cm in diameter. USG
was not performed. FNAC was  highly suspicious of angiosarcoma
and the diagnosis was conﬁrmed on core needle biopsy. A mod-
iﬁed radical mastectomy was performed. The cut surface of the
tumour appeared spongy and haemorrhagic. Microscopic examina-
tion of the mass demonstrated many dilated vascular spaces lined
and surrounded by clusters of spindle cells suggestive of grade II
angiosarcoma. On immunohistochemistry the tumour was  posi-
tive for CD31. At two-month follow-up the patient was  free of any
evidence of recurrence.
3. Discussion
Angiosarcomas are the most common sarcoma of the breast but
are still relatively rare. The neoplasm is of vascular origin. The fre-
Open access under CC BY-NC-ND license.quency of this rare tumour is 0.04% of primary breast tumours1 and
approximately 8% of breast sarcomas. Angiosarcoma can occur in
the breast as a primary lesion or as a secondary lesion as in chroni-
cally lymphedematous arms after axillary treatment for carcinoma
ess under CC BY-NC-ND license.
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Iig. 1. Microscopic photograph of angiosacoma of breast stained by H & E stain
nder low magniﬁcation.
Stewart–Treves syndrome) and as a complication of breast radia-
ion treatments.
Primary angiosarcomas usually occur in young women (20–50
ears).2,3
Angiosarcoma occurs almost exclusively in the female breast,
ith only ﬁve cases of male breast angiosarcoma reported in the
iterature.
Angiosarcoma may  have an insidious clinical onset, presenting
s a painless often discrete palpable mass that grows rapidly.4,5
ome patients complain of a painful mass with tenderness. Approx-
mately 2% of patients may  present with diffuse enlargement of
he breast. However, a bluish red discolouration of the overly-
ng skin may  be there.5 Nipple retraction, discharge, or axillary
ode enlargement are generally absent. In most reported cases,
he tumour size is >4 cm in diameter.6 Most reports indicate that
umour size does not correlate with survival. The tumour size
t discovery can reach 4 cm in diameter. Bilateral tumours have
een reported and several cases have been diagnosed in the post-
enopausal women.
On mammograms, angiosarcomas appear as an ill-deﬁned mass
nd lack the spiculations often seen in breast carcinomas. Rarely,
he tumour may  show a soap bubble appearance with a mean
ize of about 4.5 cm.  They rarely manifest coarse non-branching
icrocalciﬁcations.7
Sonography usually shows a solid mass that may  have
ell-deﬁned or lobulated margins, with both hypoechoic and
yperechoic appearance. There is often no acoustic shadowing.7
Magnetic resonance imaging (MRI) of angiosarcoma shows a
ass with low signal intensity on T1-weighted images, but high
ignal intensity on heavily T2-weighted images. The latter suggests
he presense of vascular channels containing slowﬂowing blood.7,8
Preoperative diagnosis, by FNAC and biopsy, may  be difﬁcult.
hen et al. reported that the false negative rate of percutaneous
iopsy was 37%.9 The differential diagnoses of this rare malignancy
nclude benign haemangioma, cystosarcoma phyllodes, stromal
arcoma, metaplastic carinoma, ﬁbrosarcoma, liposarcoma, and
eactive spindle cell proliferative lesions.6,10 Large-core biopsies
ight facilitate the correct diagnosis as they provide a larger
ample,11 but such a macrobiopsy is often difﬁcult to perform due to
he vascular nature of these tumours. Surgical resection and micro-
copic examination of sufﬁcient sampling of the tumour are often
ecessary to render a ﬁnal diagnosis (Figs. 1 and 2).
The histologic features of angiosarcoma of the breast arelassiﬁed into grades I, II and III. Angiosarcomas have a wide
ange of histological appearances from well-differentiated grade
 tumours consisting inﬁltrating bland vascular channels to poorlyFig. 2. Microscopic photograph of angiosacoma of breast stained by H & E stain
under high magniﬁcation.
differentiated grade III tumours with a sarcomatous spindle cell
pattern. Large amounts of blood are often present. Papillary clus-
ters of tumours cells, which can be mistaken for ductal carcinoma in
situ, may  also occur. Factor VIII and CD31 immunostaining conﬁrms
the diagnosis.
Primary angiosarcoma of the breast tends to metastasise
haematogenously to lungs, liver, bones, skin and the contralateral
breast (from the other breast).
As angiosarcomas of the breast are very rare, there is no
established standard treatment. Mastectomy is the mainstay
of treatment. Although some individuals seem to beneﬁt from
chemotherapy, it is of minimal beneﬁt for patients with dissem-
inated disease. Paclitaxel has been shown to produce excellent
response in a number of studies in patients with primary angiosar-
coma of breast.12 Immunotherapy may  also play a part in treating
this rare type of breast cancer. Recently, an approach to attack-
ing a proliferative endothelium has been extensively investigated.
New agents against angiogenesis, such as bevacizumab13 or
rapamycin,14 might also be useful against this tumour.
According to Rosen’s study, the 5 years disease free survival rate
for low grade tumours can be as high as 76% and up to 70% for
intermediate grade tumours. Whereas 5 years survival rate for high
grade tumours is about 15%.15
4. Conclusion
The importance of this case report is that primary breast
angiosarcoma is a rare disease which can develop without prior
exposure of the breast to either surgery or irradiation. A mass that
shows heterogeneous hyperechogenicity on ultrasound with an
associated architectural distorted appearance and typical malig-
nant characteristics should alert the radiologist to a possible
diagnosis of angiosarcoma. Core cut biopsy is the most important
method of making the diagnosis of primary breast angiosarcoma.
Total mastectomy remains the most effective mode of treatment.
Skin thickening should be evaluated thoroughly and if necessary
biopsied to exclude malignant inﬁltration. Although no clinical trial
has yet proven any beneﬁt from adjuvant chemotherapy or radia-
tion therapy in managing angiosarcoma, both therapies should be
considered in patients at high risk of recurrence.Conﬂict of interest statement
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